scholarly journals Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

2020 ◽  
Author(s):  
Herng-Sheng Lee ◽  
Hsin-Hao Chao ◽  
Wan-Ting Huang ◽  
Solomon Chih-Cheng Chen ◽  
Hsin-Yi Yang
Keyword(s):  
Iron Deficiency ◽  
Sleep Disorders ◽  
Psychiatric Disorders ◽  
Iron Deficiency Anemia ◽  
Lower Risk ◽  
Iron Supplementation ◽  
Psychotic Disorders ◽  
Psychiatric Morbidity ◽  
Deficiency Anemia ◽  
Increased Risk

Abstract Background: It has been shown that iron deficiency anemia (IDA) is associated with psychosocial consequences and psychiatric morbidity. However, the association between adults with IDA and psychiatric disorders has not been clarified. The purpose of this study was to investigate the psychiatric disorder morbidity of an IDA group in comparison with a non-IDA group and to examine the risk of psychiatric disorders in IDA patients treated with iron supplementation. Methods: All study subjects were 20 years of age or over with newly diagnosed IDA enrolled in the Taiwan National Health Insurance Database from 2000 to 2012. We matched IDA and non-IDA subjects according to age and gender in a 1:2 ratio. Our primary outcome was diagnosis of psychiatric disorders and the patients were monitored until the end of 2013. A multivariate Cox proportional hazards regression model was used to explore the risk of psychiatric disorders in patients with IDA after adjustment for confounders, including demographic characteristics and comorbidities. Results: The adjusted hazard ratios (aHRs) of psychiatric disorders was 1.49 (95% CI = 1.43–1.56) in the IDA group compared with the non-IDA group. Among the different types of psychiatric disorders, the IDA group was associated with significantly higher incidence and risks of dementia, anxiety disorders, depression, sleep disorders, and psychotic disorders ( p < 0.05). Furthermore, iron supplementation in IDA subjects was associated with a significantly lower risk of psychiatric disorders compared to non-iron supplementation in IDA patients. Conclusions: Our study indicates that IDA subjects had an increased risk of psychiatric disorders, regardless of other confounders. In IDA patients, iron supplementation was associated with a decreased risk of psychiatric disorders. Moreover, IDA patients receiving iron supplementation also had a lower risk of sleep disorders.

scholarly journals Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis

2019 ◽  
Author(s):  
Herng-Sheng Lee ◽  
Hsin-Hao Chao ◽  
Wan-Ting Huang ◽  
Solomon Chih-Cheng Chen ◽  
Hsin-Yi Yang
Keyword(s):  
Iron Deficiency ◽  
Sleep Disorders ◽  
Psychiatric Disorders ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Psychotic Disorders ◽  
Psychiatric Morbidity ◽  
Cox Proportional Hazards ◽  
Deficiency Anemia ◽  
Increased Risk

Abstract Background It has been shown that iron deficiency anemia (IDA) is associated with psychosocial consequences and psychiatric morbidity. However, the association between adults with IDA and psychiatric disorders has not been clarified. The purpose of this study is to investigate the psychiatric disorders morbidity of IDA in comparison with non-IDA group and to examine the risk of psychiatric disorders in IDA patients treated with iron supplementary.Methods All study subjects aged ≥ 20 years with newly diagnosed IDA in the Taiwan National Health Insurance Database during 2000-2012 were enrolled. We matched IDA and non-IDA subjects according to age and gender in a 1:2 ratio. Our primary outcome was diagnosis of psychiatric disorders and the patients were monitored until the end of 2013. The Cox proportional hazards regression model was used to evaluate the risk of psychiatric disorders events to occur in IDA.Results The adjusted hazard ratios (aHR) of psychiatric disorders was 1.49 (95% CI = 1.43 – 1.56) in the IDA group compared with the non-IDA group. Among the different type of psychiatric disorders occurrence, the IDA group was associated with significantly higher incidence and risks of dementia, anxiety disorders, depression, sleep disorders and psychotic disorders (p < 0.05). Furthermore, iron supplementation use to IDA subjects was associated with significantly lower risk of psychiatric disorders compared with IDA patients without iron supplementation.Conclusions Our study indicates that IDA had an increased risk of psychiatric disorders, regardless of other confounders. Moreover, in IDA patients, iron supplementation use could reduce the risk of psychiatric disorders, especially sleep disorders.

scholarly journals Risk of migraine in iron deficiency anemia patients with or without iron supplementation usage: a nationwide database analysis

2021 ◽  
Author(s):  
Herng-Sheng Lee ◽  
Shih-Yu Lee ◽  
Wan-Ting Huang ◽  
Solomon Chih-Cheng Chen ◽  
Hsin-Yi Yang
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Deficiency Anemia ◽  
Rank Test ◽  
Increased Risk ◽  
Taiwan National Health Insurance

IntroductionThis study evaluated the association between iron deficiency anemia (IDA) and migraine and investigated the effects of iron supplementation, and comorbid conditions, including cardiovascular, respiratory, hepatic, endocrine, metabolic, and other diseases on migraine development.Material and methodsAll study subjects aged ≥20 years with newly diagnosed IDA in the Taiwan National Health Insurance Database during 2000–2012 were enrolled. We matched IDA and non-IDA subjects according to age and sex at a 1:2 ratio. Our primary outcome was diagnosis of migraine, and the patients were monitored until the end of 2013. A Cox proportional hazards regression model was used to evaluate the risk of migraine events in IDA.ResultsThe cumulative incidence of migraine in patients with IDA was 5.82 per 1,000 person-years, which was higher than that in the comparison group (3.99 per 1,000 person-years) during the follow-up period (log-rank test, p < 0.001). After controlling for potentially confounding factors, the risk of migraine was higher in the IDA group compared with the non-IDA group (the adjusted hazard ratio = 1.68, 95% CI = 1.51−1.87, p < 0.001). Female and ≤50 year-old IDA patients with or without iron supplementation use had an increased incidence of migraine (p < 0.05).ConclusionsOur study provided additional evidence of an increased risk of migraine in patients with IDA. We also found that females and ≤50 year-old IDA patients with or without iron supplementation use had an increased risk of migraines.

scholarly journals Association of Iron Supplementation Programs with Iron-Deficiency Anemia Outcomes among Children in Brazil

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1524
Author(s):  
Carolina Thalya da Silva Paulino ◽  
Marislei Nishijima ◽  
Flavia Mori Sarti
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Fixed Effects ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Federal Programs ◽  
Government Programs ◽  
Lengths Of Stay ◽  
Social Inequities ◽  
High Prevalence

Anemia remains a condition with high prevalence in populations worldwide, and the prevalence of anemia among children under five years old in Brazil is approximately 40%, being higher in communities marked by social inequities. Diverse government programs during recent decades targeted iron-deficiency anemia, considering its impacts throughout the lifetime. The objective of this study was to investigate the effects of two government iron supplementation programs on health outcomes related to iron-deficiency anemia among children up to 4 years old in Brazilian municipalities. A longitudinal panel encompassing data from 5570 municipalities from 1998 to 2019 was investigated using a difference-in-differences framework with multiple interventions and distinct times of adhesion, and fixed-effects models were estimated to control for invariant municipal characteristics throughout the period in order to ensure comparability. The results indicate significant effects of the federal programs in reducing hospitalizations and lengths of stay due to iron-deficiency anemia, especially in non-poor municipalities. There was complementarity in the effects of the programs; however, neither of the programs influenced mortality rates. Thus, it is important to consider possible improvements in the operationalization of the programs, in order to achieve better results in the reduction of severe iron-deficiency anemia among children up to 4 years old.

Role of Iron Supplementation in Reducing Severity of Depression: A Review

2020 ◽  
pp. 67-76
Author(s):  
OJS Admin
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Reproductive Age ◽  
Deficiency Anemia ◽  
Essential Nutrient ◽  
Severity Of Depression ◽  
The Impact ◽  
Clinical Problems

Depression is a public health disorder, ranking third after respiratory and cardiac diseases. There were many evidences that iron deficiency anemia (IDA) is one of the foremost causes regarding nutritional pointof view for depression. We reviewed these evidences that IDAlinking to depression. We identified seventeen studies in four databases including randomized-controlled trials (RCTs) and observational studies assessing the impact of IDAand iron supplementation on the risk of depression. We extracted data on the basis of sample size, geographical region, measures of depression, hemoglobin, iron levels and intake of iron supplementation and critically appraised the results from the studies. Eleven out of sixty one studies were experimental, which indicated that dietary supplementation particularly iron supplementation had an association (r − 0.19 to −0.43 and ORs 1.70–4.64) with severity of depression. Evidences showed that women of reproductive age were more vulnerable to iron deficiency anemia than other population. Low ferritin and low hemoglobin level were associated with severity of depression. Iron is an essential nutrient for all living creatures, as a cofactor of various enzymes and plays significant role in environmental stimulant for the articulation of numerous virulence factors. Many clinical problems are caused by iron deficiency. Therefore, this review intended to highlight the important role of iron supplementation in reducing the severity of depression.

Effects of Different Doses and Duration of Iron Supplementation on Curing Iron Deficiency Anemia: an Experimental Study

2014 ◽  
Vol 162 (1-3) ◽  
pp. 242-251 ◽  
Author(s):  
Juan Ma ◽  
Xiaosha Wen ◽  
Fengfeng Mo ◽  
Xiaoli Wang ◽  
Zhilei Shen ◽  
...  
Keyword(s):  
Experimental Study ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Different Doses

scholarly journals Iron supplementation in goitrous, iron-deficient children improves their response to oral iodized oil

2000 ◽  
pp. 217-223 ◽  
Author(s):  
M Zimmermann ◽  
P Adou ◽  
T Torresani ◽  
C Zeder ◽  
R Hurrell
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Thyroid Volume ◽  
Oral Iron ◽  
Deficiency Anemia ◽  
Urinary Iodine Concentration ◽  
Iodized Oil ◽  
Iron Deficient ◽  
Group 2

OBJECTIVE: In developing countries, many children are at high risk for both goiter and iron-deficiency anemia. Because iron deficiency may impair thyroid metabolism, the aim of this study was to determine if iron supplementation improves the response to oral iodine in goitrous, iron-deficient anemic children. DESIGN: A trial of oral iodized oil followed by oral iron supplementation in an area of endemic goiter in the western Ivory Coast. METHODS: Goitrous, iodine-deficient children (aged 6-12 years; n=109) were divided into two groups: Group 1 consisted of goitrous children who were not anemic; Group 2 consisted of goitrous children who were iron-deficient anemic. Both groups were given 200mg oral iodine as iodized oil. Thyroid gland volume using ultrasound, urinary iodine concentration (UI), serum thyroxine (T(4)) and whole blood TSH were measured at baseline, and at 1, 5, 10, 15 and 30 weeks post intervention. Beginning at 30 weeks, the anemic group was given 60mg oral iron as ferrous sulfate four times/week for 12 weeks. At 50 and 65 weeks after oral iodine (8 and 23 weeks after completing iron supplementation), UI, TSH, T(4) and thyroid volume were remeasured. RESULTS: The prevalence of goiter at 30 weeks after oral iodine in Groups 1 and 2 was 12% and 64% respectively. Mean percent change in thyroid volume compared with baseline at 30 weeks in Groups 1 and 2 was -45.1% and -21.8% respectively (P<0.001 between groups). After iron supplementation in Group 2, there was a further decrease in mean thyroid volume from baseline in the anemic children (-34.8% and -38.4% at 50 and 65 weeks) and goiter prevalence fell to 31% and 20% at 50 and 65 weeks. CONCLUSION: Iron supplementation may improve the efficacy of oral iodized oil in goitrous children with iron-deficiency anemia.

Sign in / Sign up

Export Citation Format

Share Document